How rigorous research built a $US141bn company, Moderna

Moderna co-founder Robert Langer says vaccine development for a range of diseases – not just Covid-19 – will be one of the biggest trends among biotechnology in coming years.

Jared Lynch

How rigorous research built a $US141bn company, Moderna

October 27, 2021
Moderna co-founder Robert Langer says vaccine development for a range of diseases – not just Covid-19 – will be one of the biggest trends among biotechnology in coming years.
Read Transcript

Having launched more than a dozen biotech companies, including mRNA vaccine producer Moderna, the question Robert Langer gets asked the most is “what is the next big thing”.

After all, investing in biotechs is not for the faint of heart. For every unicorn that emerges there are scores that fall over in clinical trials. But Dr Langer has a knack of knowing what works, with his 3 per cent stake in Moderna catapulting him into the billionaires’ club.

Since it listed on the Nasdaq in 2018, Moderna’s value has soared from $US7.5bn to $US141bn ($188bn), largely thanks to it developing a highly effective vaccine against Covid-19.

But long before the pandemic, Dr Langer knew he was onto a winner with Moderna, a portmanteau of mode and RNA.

“I’m not surprised that it’s successful,” Dr Langer said ahead of speaking at the Sohn Hearts & Minds investor conference.

“I mean back in 2010 when we started, I remember coming home and telling my wife this was going to be the most successful biotech company ever. I just felt that the right elements – the right technology, the right people involved.”

But none of it would have happened without decades of rigorous research into messenger RNA technology, which instructs the body’s cells to make a protein that triggers an immune response against diseases such as Covid-19.

Dr Langer is quick to highlight this grunt work and the importance of R & D when people approach him at conferences and other events, asking “what will be the next big thing”.

“My answer is that it hasn‘t been invented yet,” he said.

“It is really important to support basic research, so that people can invent the things of the future that don‘t exist. That’s the most common question people always ask – what’s going to be the big thing in the next five years?

“Of course it depends whether you’re talking about something clinical or something that can be transformative like messenger RNA or nanotechnology or CRISPRs and things like that.”

Still, many biotechs are aiming to capture that next big thing, whether it was the race to develop a Covid vaccine or developing a treatment for a rare disease. Before a biotech embarks on clinical trials, the blue sky potential appears endless, only to end up in heartache when things don’t go to plan.

Even established players like Australia’s biggest health company CSL has had some misses, like its homegrown Covid-19 vaccine it was developing with the University of Queensland which it aborted after trials revealed it triggered false positives for HIV.

So what’s Dr Langer’s secret in picking what flies?

“Well, I guess if I were to pick a formula, it is to take a really transforming scientific idea, that would be number one, but that’s also like what I call platform technology, meaning you could use it over and over again, for different things, different diseases for example or different types of drugs.

“That’s validated by in vivo data and by excellent scientific papers. In fact, one thing investors ought to look and see where some of the seminal papers that lead to that company are published. Are they published in top journals like Science or Nature, or not? And that they have very good intellectual property, that they have excellent business people, that they have excellent investors, that would be my general area.”

For the near term, a spotlight is going to be cast on vaccination – and not just for Covid-19, which most health experts are expecting will be part of our lives for decades, requiring booster shots and research into more next generation vaccines to combat challenges such as cold chain storage.

“What you’ll see is more and more vaccines being produced. We will see, at some point, better ways of delivering them to patients. And you'll certainly see a lot of vaccines based on our messenger RNA for other diseases,” Dr Langer said.

“If you look at the Moderna pipeline, there’s about nine different diseases that we're studying for vaccines.”

These include therapeutic vaccines for cancer as well as prophylactic vaccines to build immunity against viruses like Covid.

And the main thing that Dr Langer is focused on is his connection to lab work.

“The major thing I still do is run my academic lab. To me it’s a team effort. My students want see their doctoral work or postdoctoral work lead to products that could help people and I want to see that happen too.

“It’s really been a team effort I’ve had the good fortune of working with some excellent investors, excellent CEOs. The science part I can help a lot with but I’ve had the good fortune of working with very good people in the other areas and that’s been key.”

And in his lab could be the next big thing. About 150 people in his team are working on a range of projects from a single-step method – meaning all its takes is one dose to inoculate someone against a disease for life – pills that only need to be taken once a week, a month or even a year; and children’s nutrition.

“We’re working on new children’s pills. We’re also working on new ways of giving nutrition. There’s about 2 billion children or people that are malnourished, we’re working on ways of also delivering nutrients much better to people,” Dr Langer said.

“And then the other giant area that we work on in our lab we started many years ago called tissue engineering, which is ways of making new tissues and organs from scratch. That’s actually led to skin for burn victims, there are clinical trials for making new blood vessels and there are other clinical trials for spinal cord repair, hearing loss. So there are all kinds of things you could do.”

The 2021 Sohn Hearts & Minds Conference will be held on December 3. Tickets and details at sohnheartsandminds.com.au

 

The article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

 

Having launched more than a dozen biotech companies, including mRNA vaccine producer Moderna, the question Robert Langer gets asked the most is “what is the next big thing”.

After all, investing in biotechs is not for the faint of heart. For every unicorn that emerges there are scores that fall over in clinical trials. But Dr Langer has a knack of knowing what works, with his 3 per cent stake in Moderna catapulting him into the billionaires’ club.

Since it listed on the Nasdaq in 2018, Moderna’s value has soared from $US7.5bn to $US141bn ($188bn), largely thanks to it developing a highly effective vaccine against Covid-19.

But long before the pandemic, Dr Langer knew he was onto a winner with Moderna, a portmanteau of mode and RNA.

“I’m not surprised that it’s successful,” Dr Langer said ahead of speaking at the Sohn Hearts & Minds investor conference.

“I mean back in 2010 when we started, I remember coming home and telling my wife this was going to be the most successful biotech company ever. I just felt that the right elements – the right technology, the right people involved.”

But none of it would have happened without decades of rigorous research into messenger RNA technology, which instructs the body’s cells to make a protein that triggers an immune response against diseases such as Covid-19.

Dr Langer is quick to highlight this grunt work and the importance of R & D when people approach him at conferences and other events, asking “what will be the next big thing”.

“My answer is that it hasn‘t been invented yet,” he said.

“It is really important to support basic research, so that people can invent the things of the future that don‘t exist. That’s the most common question people always ask – what’s going to be the big thing in the next five years?

“Of course it depends whether you’re talking about something clinical or something that can be transformative like messenger RNA or nanotechnology or CRISPRs and things like that.”

Still, many biotechs are aiming to capture that next big thing, whether it was the race to develop a Covid vaccine or developing a treatment for a rare disease. Before a biotech embarks on clinical trials, the blue sky potential appears endless, only to end up in heartache when things don’t go to plan.

Even established players like Australia’s biggest health company CSL has had some misses, like its homegrown Covid-19 vaccine it was developing with the University of Queensland which it aborted after trials revealed it triggered false positives for HIV.

So what’s Dr Langer’s secret in picking what flies?

“Well, I guess if I were to pick a formula, it is to take a really transforming scientific idea, that would be number one, but that’s also like what I call platform technology, meaning you could use it over and over again, for different things, different diseases for example or different types of drugs.

“That’s validated by in vivo data and by excellent scientific papers. In fact, one thing investors ought to look and see where some of the seminal papers that lead to that company are published. Are they published in top journals like Science or Nature, or not? And that they have very good intellectual property, that they have excellent business people, that they have excellent investors, that would be my general area.”

For the near term, a spotlight is going to be cast on vaccination – and not just for Covid-19, which most health experts are expecting will be part of our lives for decades, requiring booster shots and research into more next generation vaccines to combat challenges such as cold chain storage.

“What you’ll see is more and more vaccines being produced. We will see, at some point, better ways of delivering them to patients. And you'll certainly see a lot of vaccines based on our messenger RNA for other diseases,” Dr Langer said.

“If you look at the Moderna pipeline, there’s about nine different diseases that we're studying for vaccines.”

These include therapeutic vaccines for cancer as well as prophylactic vaccines to build immunity against viruses like Covid.

And the main thing that Dr Langer is focused on is his connection to lab work.

“The major thing I still do is run my academic lab. To me it’s a team effort. My students want see their doctoral work or postdoctoral work lead to products that could help people and I want to see that happen too.

“It’s really been a team effort I’ve had the good fortune of working with some excellent investors, excellent CEOs. The science part I can help a lot with but I’ve had the good fortune of working with very good people in the other areas and that’s been key.”

And in his lab could be the next big thing. About 150 people in his team are working on a range of projects from a single-step method – meaning all its takes is one dose to inoculate someone against a disease for life – pills that only need to be taken once a week, a month or even a year; and children’s nutrition.

“We’re working on new children’s pills. We’re also working on new ways of giving nutrition. There’s about 2 billion children or people that are malnourished, we’re working on ways of also delivering nutrients much better to people,” Dr Langer said.

“And then the other giant area that we work on in our lab we started many years ago called tissue engineering, which is ways of making new tissues and organs from scratch. That’s actually led to skin for burn victims, there are clinical trials for making new blood vessels and there are other clinical trials for spinal cord repair, hearing loss. So there are all kinds of things you could do.”

The 2021 Sohn Hearts & Minds Conference will be held on December 3. Tickets and details at sohnheartsandminds.com.au

 

The article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

 

Disclaimer: This material has been prepared by The Australian, published on Oct 27, 2021. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
March 14, 2025

$1.4 million boost for SA medical research

South Australian medical research will receive a $1.4 million cash injection, as a direct result of a major investment and philanthropy conference held in Adelaide.

Read More
Anthony Scaramucci’s time in the White House was brief but memorable. APAnthony Scaramucci’s time in the White House was brief but memorable. APAnthony Scaramucci’s time in the White House was brief but memorable. APAnthony Scaramucci’s time in the White House was brief but memorable. AP
May 19, 2025

Why ‘The Mooch’ thinks Trump is more dangerous this time around

Anthony Scaramucci says Trump has fewer constraints on his worst instincts in his second administration. But he still gets bored easily.

Read More
Image caption: Anthony “The Mooch” Scaramucci at the New York headquarters of his SkyBridge Capital last week. Picture: Jaclyn LichtImage caption: Anthony “The Mooch” Scaramucci at the New York headquarters of his SkyBridge Capital last week. Picture: Jaclyn LichtImage caption: Anthony “The Mooch” Scaramucci at the New York headquarters of his SkyBridge Capital last week. Picture: Jaclyn LichtImage caption: Anthony “The Mooch” Scaramucci at the New York headquarters of his SkyBridge Capital last week. Picture: Jaclyn Licht
May 19, 2025

My biggest mistake: Anthony Scaramucci on what makes Donald Trump tick

On Elon Musk, money and the White House, fast-talking Wall Street hedge fund manager and former Trump communications director Anthony Scaramucci tells it as he sees it.

Read More
A bull case for Bitcoin even as it trades near record levels. Picture: AFPA bull case for Bitcoin even as it trades near record levels. Picture: AFPA bull case for Bitcoin even as it trades near record levels. Picture: AFPA bull case for Bitcoin even as it trades near record levels. Picture: AFP
May 19, 2025

Bitcoin ‘on track’ for $US200,000: Anthony Scaramucci

Bitcoin could hit as much as $US200,000 ($311,000) by the end of this year, fuelled by surging inflows into exchange-traded funds and Donald Trump’s erratic policymaking.

Read More
Anthony Scaramucci says America has no choice but to lower tariffs on China further. Jaclyn LichtAnthony Scaramucci says America has no choice but to lower tariffs on China further. Jaclyn LichtAnthony Scaramucci says America has no choice but to lower tariffs on China further. Jaclyn LichtAnthony Scaramucci says America has no choice but to lower tariffs on China further. Jaclyn Licht
May 19, 2025

‘The Mooch’ says Trump will have to cut China tariffs below 10pc

Scaramucci, who is best known as The Mooch, is the first big-name global investor to be confirmed for the Sohn Hearts & Minds conference in Sydney in November.

Read More
December 19, 2024

Rikki Bannan – Don’t get caught up in momentum

Conference Fund Manager Rikki Bannan, Executive Director at IFM Investors, joins Equity Mates to discuss her standout 2023 stock pick, Telix, and explore what opportunities lie ahead.

Read More
Nick Moakes of the Wellcome Trust told the Sohn Hearts & Minds conference that some investors were too optimistic about a reduction in rates. Picture: Ben SearcyNick Moakes of the Wellcome Trust told the Sohn Hearts & Minds conference that some investors were too optimistic about a reduction in rates. Picture: Ben SearcyNick Moakes of the Wellcome Trust told the Sohn Hearts & Minds conference that some investors were too optimistic about a reduction in rates. Picture: Ben SearcyNick Moakes of the Wellcome Trust told the Sohn Hearts & Minds conference that some investors were too optimistic about a reduction in rates. Picture: Ben Searcy
November 20, 2024

Trump unifies top investors in decade-long bullish outlook for US

Nick Moakes, CIO of the $72 billion Wellcome Trust, told the conference that too many investors were banking on a return to the ultra-low interest rates that prevailed over the past decade.

Read More
Wall Street legend Howard Marks told the Sohn event that US exceptionalism would endure. Picture: Ben SearcyWall Street legend Howard Marks told the Sohn event that US exceptionalism would endure. Picture: Ben SearcyWall Street legend Howard Marks told the Sohn event that US exceptionalism would endure. Picture: Ben SearcyWall Street legend Howard Marks told the Sohn event that US exceptionalism would endure. Picture: Ben Searcy
November 17, 2024

Is anyone brave or stupid enough to bet against America?

Stock pickers have been punished for betting against the US. The choice between consensus and contrarianism on American exceptionalism is now harder than ever.

Read More
Ellerston Capital's Chris Kourtis says things will improve at embattled fund manager Perpetual. Picture: Ben Searcy PhotographyEllerston Capital's Chris Kourtis says things will improve at embattled fund manager Perpetual. Picture: Ben Searcy PhotographyEllerston Capital's Chris Kourtis says things will improve at embattled fund manager Perpetual. Picture: Ben Searcy PhotographyEllerston Capital's Chris Kourtis says things will improve at embattled fund manager Perpetual. Picture: Ben Searcy Photography
November 15, 2024

Eleven stock tips from Sohn to get you through 2025

“There’s no finer place for the finance festival than in the festival city,” said Matthew Grounds. He, along with fellow Barrenjoey co-executive chairman Guy Fowler and investor Gary Weiss, is one of Sohn’s driving forces.

Read More
November 15, 2024

Howard Marks and Sohn’s big stars reveal seven rules for investing

Among the stock picks and stunts at the Sohh Hearts & Minds event, Howard Marks and Nick Moakes provided investors with long-term rules for playing markets.

Read More
November 15, 2024

Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Read More
Markets will have to adjust to a world in which a new Donald Trump presidency will continue to ‘bash’ Xi Jinping’s China. Picture: AFPMarkets will have to adjust to a world in which a new Donald Trump presidency will continue to ‘bash’ Xi Jinping’s China. Picture: AFPMarkets will have to adjust to a world in which a new Donald Trump presidency will continue to ‘bash’ Xi Jinping’s China. Picture: AFPMarkets will have to adjust to a world in which a new Donald Trump presidency will continue to ‘bash’ Xi Jinping’s China. Picture: AFP
November 15, 2024

Sohn investors position for bullish but bumpy Trump ride

Australia and the rest of the world must adjust to a new Trump presidency that will deliver an expected bull market but also disruption, with the leader in waiting prepared to “create pain” to get his way.

Read More
November 15, 2024

Sohn stock picker experts name best shares to invest in for year ahead

‍Don’t overlook down and out silver miners, legacy skincare brands ready for a revival and a big financial company suffering from a severe case of shareholder wealth destruction.

Read More
November 15, 2024

Sohn: NYSE-listed Estee Lauder’s Northcape Capital pick

Northcape Capital’s Fleur Wright this gives a rare opportunity to buy a high quality company at an attractive price.

Read More
Mike Novogratz, CEO of Galaxy Digital. Photo: Jutharat Pinyodoonyachet/BloombergMike Novogratz, CEO of Galaxy Digital. Photo: Jutharat Pinyodoonyachet/BloombergMike Novogratz, CEO of Galaxy Digital. Photo: Jutharat Pinyodoonyachet/BloombergMike Novogratz, CEO of Galaxy Digital. Photo: Jutharat Pinyodoonyachet/Bloomberg
November 9, 2024

Galaxy Digital CEO Mike Novogratz believes bitcoin will hit $US100k

Bitcoin’s bounce to record highs in recent days is only the beginning of a fresh surge higher for cryptocurrency, says US billionaire Mike Novogratz.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lancaster sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.